NEULANDLABBSENeuland Laboratories LtdLowNeutral
Announced Tue, 12 May · 17:15 IST

Error in the Earnings Call Link

Investor Communications View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹17100.00
prior close
₹18305.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0
Up moveDown movePending
AI summary

Neuland Laboratories has submitted a regulatory filing correcting an error in the earnings call link from their May 12, 2026 press release. The filing includes the Q4FY26 financial results showing strong performance with total income of Rs. 788.7 crore, up 134.9% YoY from Rs. 335.8 crore in Q4FY25. EBITDA surged to Rs. 319.4 crore versus Rs. 58.2 crore in the prior year period. EBITDA margin expanded significantly to 40.5% from 17.3%, a 2316 basis points improvement. Profit after tax reached Rs. 212.5 crore compared to Rs. 27.7 crore in Q4FY25. The CEO noted good business visibility in the short to medium term supported by commercial and near-commercial molecules, with investments in Peptide Manufacturing and a new R&D Centre proceeding as planned.

Likely market impact

The filing is primarily an administrative correction but contains strong Q4FY26 results with exceptional margin expansion and profitability growth. The margin improvement from 17.3% to 40.5% is notably positive for shareholders, though the lack of formal guidance in this filing means investors should await the earnings call for management commentary on sustainability of these margins.